donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

KNSA Kiniksa Pharmaceuticals

9.790
-0.550-5.32%
Close 06/28 16:00 ET
9.680
-0.11-1.12%
Post Mkt Price 06/28 19:37 ET
High
10.360
Open
10.320
Turnover
2.98M
Low
9.660
Pre Close
10.340
Volume
299.77K
Market Cap
678.21M
P/E(TTM)
Loss
52wk High
16.679
Shares
69.28M
P/E(Static)
Loss
52wk Low
7.360
Float Cap
261.75M
Bid/Ask %
81.82%
Historical High
32.880
Shs Float
26.74M
Volume Ratio
0.68
Historical Low
5.010
Dividend TTM
--
Div Yield TTM
35
P/B
4.08
Dividend LFY
--
Div Yield LFY
357.51%
Turnover Ratio
1.12%
Amplitude
6.77%
Avg Price
9.937
Lot Size
1
Float Cap
261.75M
Bid/Ask %
81.82%
Historical High
32.880
Shs Float
26.74M
Volume Ratio
0.68
Historical Low
5.010
Dividend TTM
--
P/B
4.08
Dividend LFY
--
Turnover Ratio
1.12%
Amplitude
6.77%
Avg Price
9.937
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
CEO: Patel, Sanj K.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...